MedTrace Logo

Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11)

NCT04912609 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2022-08-03

No results posted yet for this study

Summary

Hereditary spastic paraparesis type 11 (SPG11) is caused by mutations in the SPG11 gene that produces spatacsin, a protein involved in lysosomal function.

Conditions

  • Hereditary Spastic Paraplegia
  • Spastic Paraplegia Type 11

Sponsors & Collaborators

  • IRCCS Fondazione Stella Maris

    lead OTHER

Principal Investigators

  • Filippo M Santorelli, MD PhD · Filippo Santorelli-Lab Med Molecolare

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-04-30
Completion
2022-07-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04912609 on ClinicalTrials.gov